Expands requirements for health insurance carriers concerning prostate cancer screening and requires coverage be provided without cost sharing.
Summary
S1796 expands New Jersey health insurance coverage requirements for prostate cancer screening. It amends existing statutes governing health service corporations, hospital service corporations, medical service corporations, group health insurance policies, health maintenance organizations, and several state-administered health benefit programs to require coverage for an annual prostate cancer screening in accordance with the latest nationally recognized clinical practice guidelines.
The bill also requires that the screening be covered without deductible, coinsurance, copayment, or other cost-sharing requirements. It applies this mandate to individual health insurance policies, individual health benefits plans, small employer health benefits plans, the State Health Benefits Program, and the School Employees’ Health Benefits Program, with a delayed effective date for certain individual market policies until January 1, 2027. The bill includes conforming language for high-deductible health plans and catastrophic plans to the extent allowed under federal law.
Impact
The bill would broaden the scope of mandated preventive coverage under New Jersey insurance law by replacing older, more specific prostate screening language with a requirement tied to current nationally recognized clinical practice guidelines. It would affect multiple categories of insurers and plans, including commercial carriers, HMOs, and state employee and school employee benefit programs, and would likely increase the number of covered screening services and follow-up tests that must be paid for without cost sharing. The bill preserves federal-law limitations for high-deductible health plans and health savings account-compatible coverage.
Sentiment
The available voting history shows clear committee support: the Senate Commerce Committee reported the bill with amendments by a 5-0 vote. The bill’s sponsors and co-sponsors suggest broad bipartisan interest, and the text reflects a preventive-care framing focused on early detection and access to screening. No opposing testimony or recorded floor debate was provided, so the overall sentiment in the available record appears favorable and noncontroversial at the committee stage.
Contention
The main policy issue is the breadth of the mandate and how it interacts with insurance design, especially the requirement that screening be covered without cost sharing and the application to high-deductible and catastrophic plans only to the extent permitted by federal law. Another point of potential contention is the bill’s reliance on “latest nationally recognized clinical practice guidelines,” which gives medical organizations and insurers more flexibility than the prior statute but may raise questions about which screenings and follow-up tests are included. The delayed applicability date for certain individual market policies may also reflect implementation concerns.
Carry Over
Expands requirements for health insurance carriers concerning prostate cancer screening and requires coverage be provided without cost sharing.
Carry Over
Expands requirements for health insurance carriers concerning prostate cancer screening and requires coverage be provided without cost sharing.